Replies to post #323359 on Amarin Corp Plc (AMRN)

[HDGabor]

v-

(Old and not completed ... more DD is required ... but it on my list also)

• NASH
• The open-label MAD study was designed to assess safety, tolerability and pharmacokinetics of CRV431, administered orally to healthy volunteers, once daily for 28 days. The study examined doses of 75 mg, 150 mg, 225 mg, 300 mg and 375 mg.
• "Hepion's ongoing Phase 2a NASH trial is based on CRV431's demonstrated tolerability in our Phase 1 MAD study," said Dr. Stephen Harrison, Hepion's Consultant Medical Director. ... started before end of Phase 1 (good (?) sign)

Best,
G

[ggwpq]

vtem, I am no NASH expert, HDG is much better on that. However, I think HEPA is a good spec. It did raise via a secondary end of last year so there is no near term dilution risk. Biotech is hot lately, I'll probably take a position tomorrow for a trade. Thanks for the mention.

For further research on HEPA, I would check out:

https://seekingalpha.com/symbol/HEPA